Belsomra (suvorexant) tablets 10 mg Each tablet contains 10 mg suvorexant. This package contains 30 Tablets in 3 Blister Cards. Each Blister Card contains 10 Tablets Rx only NDC 00006-0033-30 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Whitehouse Station, NJ 08889, USA
Published June 2, 2021 · Recall initiated: March 15, 2021
Summary
FDA records drug Class II recall D-0522-2021, published June 2, 2021 and initiated March 15, 2021. Recalling firm: Cardinal Health Inc.; Status: Terminated; Reported quantity: 119 cartons; Lot: 1791139. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Cardinal Health Inc.
- Distributor
- FL, GA, SC
- Lot
- 1791139
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAEnoxaparin Sodium Injection, USP, 30 mg/0.3 mL, packaged in 0.3 mL prefilled syringes further packaged in bagsSeptember 3, 2025
- FDAXolair (omalizumab injection), 75 mg/0.5 ml, Rx only, Genentech, Inc., South San Francisco, CA 94080, NDCAugust 13, 2025
- FDARECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Takeda Pharmaceuticals USA,August 13, 2025
- FDAXolair (omalizumab injection), 150 mg/ml, 1 auto-injector, Rx only, Genentech, Inc, South San Francisco, CAAugust 13, 2025
- FDAPEDIA-LAX 66ML; NDC/UPC 301320202205; OTC; ENEMAJune 2, 2021
- FDABelsomra (suvorexant) tablets 20 mg Each tablet contains 20 mg suvorexant. This package contains 30 Tablets inJune 2, 2021
Questions about this recall
Was Belsomra (suvorexant) tablets 10 mg Each tablet contains 10 mg suvorexant. This package contains 30 Tablets in 3 Blister Cards. Each Blister Card contains 10 Tablets Rx only NDC 00006-0033-30 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Whitehouse Station, NJ 08889, USA recalled?
Yes. FDA published recall D-0522-2021 on June 2, 2021. Reported hazard: CGMP Deviations: Intermittent exposure to temperature excursion during storage.
What should I do if I have this product?
Voluntary: Firm initiated · Letter